Design Therapeutics, Inc. $DSGN Shares Bought by Almitas Capital LLC

Key Points

• Almitas Capital LLC increased its holdings in Design Therapeutics, acquiring an additional 129,229 shares, bringing its total ownership to approximately 1.9% of the company.
• Design Therapeutics' shares rose 3.6%, with its stock currently priced at $5.73, marking significant growth since its 12-month low of $2.60.
• The company reported a loss of ($0.34) EPS in its latest earnings, missing the analysts' consensus estimate of ($0.32).

Almitas Capital LLC boosted its stake in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 9.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,452,896 shares of the company's stock after acquiring an additional 129,229 shares during the quarter. Design Therapeutics comprises about 1.9% of Almitas Capital LLC's holdings, making the stock its 7th largest holding. Almitas Capital LLC owned approximately 2.56% of Design Therapeutics worth $5,608,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Frazier Life Sciences Management L.P. lifted its position in shares of Design Therapeutics by 3.2% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,953,547 shares of the company's stock worth $12,053,000 after purchasing an additional 61,000 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Design Therapeutics by 16.0% during the 4th quarter. Point72 Asset Management L.P. now owns 1,856,750 shares of the company's stock worth $11,456,000 after buying an additional 256,010 shares during the period. Driehaus Capital Management LLC lifted its holdings in Design Therapeutics by 17.7% in the 1st quarter. Driehaus Capital Management LLC now owns 913,399 shares of the company's stock worth $3,526,000 after buying an additional 137,317 shares in the last quarter. MPM Bioimpact LLC boosted its position in Design Therapeutics by 0.6% in the 1st quarter. MPM Bioimpact LLC now owns 562,943 shares of the company's stock valued at $2,173,000 after buying an additional 3,396 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Design Therapeutics by 15.2% in the 4th quarter. Northern Trust Corp now owns 388,125 shares of the company's stock valued at $2,395,000 after buying an additional 51,351 shares during the last quarter. Hedge funds and other institutional investors own 56.64% of the company's stock.

Design Therapeutics Stock Performance

Shares of NASDAQ DSGN traded up $0.34 during midday trading on Friday, reaching $6.45. 258,711 shares of the company's stock were exchanged, compared to its average volume of 171,328. Design Therapeutics, Inc. has a 52-week low of $2.60 and a 52-week high of $7.77. The business's fifty day moving average price is $4.54 and its two-hundred day moving average price is $4.21. The stock has a market capitalization of $367.33 million, a PE ratio of -5.76 and a beta of 1.61.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.02). Analysts predict that Design Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.